LuciValgan

Description

COMPOSITION:

Each film-coated tablet contains Valganciclovir HCl 496.3 mg equivalent to Valganciclovir……… 450mg.

INDICATION:

LuciValgan is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for:

Adult Patients:

• Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).

• Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.

Pediatric Patients:

• Prevention of CMV disease in kidney and heart transplant patients at high risk.

DOSAGE AND USE:

See full prescribing information for LuciValgan.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciValgan during Pregnancy and Lactation.